Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q5TAQ9
UPID:
DCAF8_HUMAN
Alternative names:
WD repeat-containing protein 42A
Alternative UPACC:
Q5TAQ9; D3DVE6; Q12839; Q4QQI6; Q53F14; Q66K50; Q68CS7; Q96E00
Background:
DDB1- and CUL4-associated factor 8, also known as WD repeat-containing protein 42A, plays a crucial role in cellular processes as a substrate receptor for the CUL4-DDB1 E3 ubiquitin-protein ligase complex. This protein's involvement in the ubiquitination pathway underscores its importance in cellular homeostasis and protein degradation.
Therapeutic significance:
Linked to Giant axonal neuropathy 2, an autosomal dominant disorder, DDB1- and CUL4-associated factor 8's mutation highlights its critical role in neural health. Understanding its function could pave the way for innovative treatments for peripheral neuropathies and potentially cardiomyopathy.